| Similar Articles |
 |
Chemistry World January 20, 2010 Phil Taylor |
Screw tightens on pay-for-delay drug deals Scrutiny of the tactics used by pharmaceutical companies to delay the entry of generics onto the market is rising on both sides of the Atlantic amid claims that the practice is costing consumers billions every year.  |
The Motley Fool January 25, 2010 Brian Orelli |
Pay-for-Delay Is Under the Spotlight It helps each side, but governments aren't thrilled with the idea.  |
The Motley Fool June 25, 2009 Brian Orelli |
Loss of a Settlement Option Earlier this month the Federal Trade Commission came out with a report arguing for limited patent protection for drugs made by biotech companies. Now it's ratcheting up its complaints about pharmaceutical and generic-drug companies as well.  |
Chemistry World July 10, 2009 Sarah Houlton |
Branded drugs' competition-free days numbered Authorities in the US and Europe are to look carefully at the tactics pharmaceutical firms use to delay competition from generic versions of their branded drugs.  |
The Motley Fool June 26, 2006 Stephen D. Simpson |
Is Novartis the Future of Generics? Merck's recent pricing action might just be the beginning of the end of generics as we know them. Investors, take note.  |
Chemistry World November 28, 2008 Matt Wilkinson |
EU claims pharma delaying tactics cost 3 billion euros Pharmaceutical manufacturers have been criticised by the EU competition commission for slowing the entry of generic medicines to the market.  |
The Motley Fool October 8, 2007 Brian Orelli |
New FDA Regulations for Drugmakers To deal with a growing backlog of pending applications, the FDA plans to stop its first-come, first-served system.  |
The Motley Fool February 28, 2008 Brian Lawler |
Benefiting From 2008's Generic Drugs While drug companies scramble to make up for lost revenue as their products are hit with patent expirations, other companies will benefit from the patent losses. Take a look at some winners and losers of drugs going off patent this year.  |
| Knowledge@Wharton |
Drug Companies and the Patent Game: Fair Play or Foul? Is legal maneuvering a legitimate attempt by the big pharmaceutical companies to recover the huge costs of developing new drugs? Or are the brand-name firms inappropriately gaming the system for their own benefit, to the detriment of consumers and insurance companies?  |
The Motley Fool March 7, 2007 Rich Duprey |
Eisai Courts Danger The start of a patent-infringement trial sets the stage for the Japanese pharmaceutical's loss of protection on a major drug.  |
Chemistry World April 2, 2007 |
European Generics Suppliers Hit Generics drug manufacturers have lost a slice of their market with the reinstatement of a European patent covering Merck's multi-billion-dollar osteoporosis drug, Fosamax.  |
The Motley Fool September 9, 2010 Jim Mueller |
Today's Buy Opportunity: Teva Pharmaceutical Take advantage of this growing generic-drug maker.  |
The Motley Fool December 29, 2006 Brian Lawler |
Lilly's Patents Stay in Bloom Even with upcoming patent expiries, Lilly isn't in nearly the same desperate situation that some of its large-cap pharma peers will be dealing with in the upcoming years. Investors, take note.  |
Pharmaceutical Executive August 1, 2005 Jill Wechsler |
Washington Report: Treating Patents It may seem unusual that a court ruling challenging patent protections is considered a victory for Big Pharma. But the decision was supported by pharmaceutical companies, along with the Justice Department, as a way to spur biomedical research and new-drug development.  |
The Motley Fool November 27, 2006 Brian Lawler |
Teva and Pfizer Make Up The companies decide to play nice over generic versions of two of Pfizer's drugs.  |
The Motley Fool January 31, 2008 Brian Orelli |
Wyeth Calls Teva's Bluff Wyeth launches a generic version of its own heartburn drug.  |
The Motley Fool December 19, 2005 Stephen D. Simpson |
Pfizer Wins, a Sector Rejoices The pharmaceutical dodges a bullet and investors find renewed enthusiasm for big-cap pharma.  |
Chemistry World May 2006 Bea Perks |
Editorial: Generics in the Dock The manufacturers of generic medicines in the U.K. must work harder to guard their good reputation. Or perhaps, manufacturers of generic medicines must work harder to counter their bad reputation.  |
Pharmaceutical Executive May 1, 2011 Stan Bernard |
Competition 2.0: Brands vs. Generics Innovator and generics companies are colliding as they invade each other's turf.  |
The Motley Fool April 25, 2006 Brian Gorman |
Pharma Plays With Fire Drugmakers' short-term gain could lead to long-term pain.  |
The Motley Fool March 13, 2008 Stephen Albainy-Jenei |
Pfizer's Celebrex Aches and Pains The Court of Appeals for the Federal Circuit upholds a lower court's ruling that found Teva Pharmaceutical had infringed two of Pfizer's patents for Celebrex.  |
The Motley Fool July 30, 2007 Brian Orelli |
Is Par Pharmaceutical Settling for Less? The generic drugmaker avoids going to court in some recent cases. Patent lawyers are the lifeblood of a generic drugmaker, and investors should want them to act as aggressively as possible so that Par can expand its product line.  |
Bio-IT World November 2005 Patrick R. Scanlon |
Patent Term Extension Primer U.S. patent law includes provisions for extending the patent term of medical devices and pharmaceuticals in instances when lengthy FDA approval is taking place during the term.  |
The Motley Fool April 22, 2011 Sean Williams |
Pharma's Most Perilous Pipelines Patent expirations expose weaknesses for these Wall Street darlings.  |
BusinessWeek April 18, 2005 Manjeet Kripalani |
India: Bigger Pharma Tougher patent protection laws are spurring rapid growth in new drug research across India.  |
Chemistry World May 8, 2015 Matthew Gunther |
Court rejects Spain's challenge to EU patent reform The European Court of Justice has dismissed a legal challenge by Spain to block the introduction of a single patent system in Europe.  |
The Motley Fool January 18, 2008 Brian Lawler |
Wrong-Way Regulators in Europe European Union regulators raided operations of multiple large pharmaceutical companies looking for antitrust and anticompetitive actions in both the branded and generic sectors. They're looking in the wrong places.  |
Chemistry World May 21, 2009 Matt Wilkinson |
Big Pharma set for generics boost Pharmaceutical firms have been rushing to ensure they minimize their losses by expanding their generics businesses and reach into emerging markets.  |
The Motley Fool December 12, 2005 Rich Duprey |
Patent? What Patent? Japanese drug firm Eisai sues Teva over a patented Alzheimer's treatment. Investors, take note.  |
Managed Care September 2006 |
Payers, Consumers Benefit as Patents Expire The generic drug market seems ready to explode, according to reports from IMS Health and the Generic Pharmaceuticals Association.  |
BusinessWeek June 24, 2010 Bliss & Decker |
Ending the Silence of Generic Drugmakers The FTC says drugmakers are paying generic rivals not to compete.  |
Pharmaceutical Executive April 1, 2014 |
Whatever Happened To Faster Reimbursement For Generics In Europe? The plan to accelerate generic pricing and reimbursement has become another tragic European casualty.  |
The Motley Fool June 22, 2006 Stephen D. Simpson |
Merck Goes on the Attack Predator becomes prey in this latest twist in the generics game. Given how much the markets hate uncertainty, that could mean that big generic drug companies might go on sale for patient long-term investors.  |
The Motley Fool October 18, 2010 Brian Orelli |
Pfizer Flexes Its Generic Muscles The pharma giant moves farther into generic drugs.  |
Managed Care September 2007 Martin Sipkoff |
Patent Law Rulings Work in Favor of Generics Thanks to recent Supreme Court rulings, manufacturers of generic drugs are in a good position to continue expansion of their market share.  |
The Motley Fool December 3, 2008 Brian Orelli |
High-Margin Generic Drugmakers -- An Oxymoron? The big profits come when a generic-drug maker doesn't have any competition.  |
CIO January 1, 2003 Christopher Koch |
Patently Stupid? It's not clear at the start of 2003 whether the software patent frenzy will cause innovation to flower or be trampled.  |
The Motley Fool July 14, 2008 Brian Orelli |
Teva Gets a Taste of Its Own Medicine Momenta Pharmaceuticals and Novartis are challenging the patents on Teva Pharmaceutical's blockbuster multiple sclerosis drug Copaxone.  |
The Motley Fool February 23, 2007 Rich Duprey |
Foolish Forecast: Barr Labs Resets Bar The pharmaceutical is set to release fourth-quarter 2006 financial results. Investors, here is what you can expect to see.  |
Pharmaceutical Executive September 1, 2012 Jill Wechsler |
Costs, Coverage, and Court Decisions Its election season and drug pricing issues are once again front and center in the policy wars on managing the high cost of healthcare.  |
Pharmaceutical Executive August 1, 2005 Sarah Houlton |
Global Report: Big Disadvantage Is the European Commission's definition of market dominance too narrow? AstraZeneca thinks so.  |
The Motley Fool October 30, 2006 Brian Lawler |
Sales Slow Down for Bristol-Myers Plavix isn't the only drug facing a challenging future. Losing patent protection and facing generic competition can be disastrous to sales and earnings if a pharmaceutical company doesn't have a way to drive revenue growth. Investors, take note.  |
The Motley Fool September 12, 2005 M.D. Mitchell |
Big Problems for Big Pharma Creating new drugs is never easy, but the companies that excel in three key areas are the ones for investors to watch.  |
The Motley Fool August 6, 2011 Sean Williams |
10 Large Caps to Rule Them All There's nothing generic about this company. For the inaugural large-cap pick, I think we should revisit pharma's most impervious pipeline, Teva Pharmaceuticals.  |
Pharmaceutical Executive October 1, 2010 |
Taking a Less-Generic Route to Generics A leading pharmaceutical industry player speaks out on what is fueling success in the sector.  |
Pharmaceutical Executive October 1, 2005 Glass & Worrell |
Whose Afraid of Authorized Generics Losing a patent challenge lets a generic competitor grab market share and slash branded profits. Sound scary? Ignoring authorized generics is worse.  |
The Motley Fool May 31, 2007 Brian Lawler |
Dueling Fools: Eli Lilly Bear Well-managed companies don't always make for good investments. This pharmaceutical powerhouse is a good example.  |
The Motley Fool January 31, 2007 Brian Lawler |
You're Only Hurting Yourself, Thailand Thailand's decision to allow generics could do more harm than good. Investors, take note.  |
The Motley Fool May 21, 2009 Brian Orelli |
If You Can't Beat 'Em, Join 'Em: Pharma Goes Generic In the battle against generic rivals, it seems pharmaceutical companies would rather switch than fight. A pair of deals heralds Big Pharma's latest moves into the generic-drug world. See what Novartis and sanofi-aventis recently did.  |
Pharmaceutical Executive October 1, 2006 Joanna Breitstein |
"I Pray for the Welfare of Your Company..." Big Pharma's drugs fill Teva Pharmaceutical's pipeline. CEO Israel Makov says he's not the enemy. To prove it, he offers lessons in survival.  |